Evoke Pharma, which is developing drugs to treat gastrointestinal disorders and diseases, raised $25 million by offering 2.1 million shares at $12, the low end of the range of $12 to $14. Evoke Pharma plans to list on the NASDAQ under the symbol EVOK. Evoke Pharma initially filed confidentially on 4/19/2013. Aegis Capital was the sole bookrunner on the deal.
